420 with CNW — Kentucky Prepares to Implement Medical Cannabis Executive Order
Last month, Kentucky Governor Andy Beshear signed an executive order that would partly legalize the use of medical cannabis. The executive order, which goes into effect on Jan. 1, 2023, will permit individuals in the state who have been diagnosed with various conditions to use and possess cannabis they purchase legally in other states.
The state of Kentucky is one of the few remaining ones in the country where it is still illegal to purchase either recreational or medical cannabis. States bordering the Bluegrass state with legal medical cannabis programs include Indiana, Ohio, Tennessee, Virginia, West Virginia, Missouri and Illinois. Of these states, only Indiana and Tennessee allow nonresidents to buy medical cannabis.
Medical conditions eligible for medical marijuana in Kentucky include cancer, intractable seizures, epilepsy, Parkinson’s disease, amytrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, hepatitis C, Crohn’s disease, muscular dystrophy, sickle cell anemia, multiple sclerosis, Huntington’s disease, PTSD, severe and chronic pain, severe arthritis, neuropathies, cachexia or wasting syndrome, intractable pain, glaucoma, HIV/AIDS and any other terminal illness. Patients will need to have valid written certification from their physicians to use or possess legally purchased cannabis. Their medical provider’s written certification should contain the name, phone number and address of the medical provider as well as the patient.
In addition, the certification should also include the medical provider’s license number, their medical diagnosis, the provider’s signature, a statement which shows a bonafide provider-patient relationship and the date. The order stipulates that individuals will not be allowed to possess more than eight ounces of cannabis at any given time within the Bluegrass state. Individuals are also advised to keep the receipt showing when and where the drug was bought.
The total number of states that have legalized the use of recreational marijuana in the country will soon be 21, following Maryland and Missouri’s success on their general election ballot measures. The state of Missouri legalized the possession of recreational cannabis on Dec. 8, 2022. However, legal sales are not expected to begin until state regulations are finalized.
Virginia, which also borders Kentucky, also legalized recreational cannabis possession last year. The state has yet to launch its legal markets. As a result, residents of Kentucky will only be able to purchase recreational cannabis legally in bordering Illinois, whenever this will be permitted. Starting in 2023, however, Kentuckians will be able to buy recreational cannabis legally in Michigan.
This growing medical use of cannabis is also motivating many companies such as India Globalization Capital Inc. (NYSE American: IGC) to go a step further and develop cannabinoid-derived formulations which, once FDA approved, could be available through the hospital system.
NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Last month, Kentucky Governor Andy Beshear signed an executive order that would partly legalize the use of medical cannabis. The executive order, which goes into effect on Jan. 1, 2023, will permit individuals in the state who have been diagnosed with various conditions to use and possess cannabis they purchase legally in other states.
The state of Kentucky is one of the few remaining ones in the country where it is still illegal to purchase either recreational or medical cannabis. States bordering the Bluegrass state with legal medical cannabis programs include Indiana, Ohio, Tennessee, Virginia, West Virginia, Missouri and Illinois. Of these states, only Indiana and Tennessee allow nonresidents to buy medical cannabis.
Medical conditions eligible for medical marijuana in Kentucky include cancer, intractable seizures, epilepsy, Parkinson’s disease, amytrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, hepatitis C, Crohn’s disease, muscular dystrophy, sickle cell anemia, multiple sclerosis, Huntington’s disease, PTSD, severe and chronic pain, severe arthritis, neuropathies, cachexia or wasting syndrome, intractable pain, glaucoma, HIV/AIDS and any other terminal illness. Patients will need to have valid written certification from their physicians to use or possess legally purchased cannabis. Their medical provider’s written certification should contain the name, phone number and address of the medical provider as well as the patient.
In addition, the certification should also include the medical provider’s license number, their medical diagnosis, the provider’s signature, a statement which shows a bonafide provider-patient relationship and the date. The order stipulates that individuals will not be allowed to possess more than eight ounces of cannabis at any given time within the Bluegrass state. Individuals are also advised to keep the receipt showing when and where the drug was bought.
The total number of states that have legalized the use of recreational marijuana in the country will soon be 21, following Maryland and Missouri’s success on their general election ballot measures. The state of Missouri legalized the possession of recreational cannabis on Dec. 8, 2022. However, legal sales are not expected to begin until state regulations are finalized.
Virginia, which also borders Kentucky, also legalized recreational cannabis possession last year. The state has yet to launch its legal markets. As a result, residents of Kentucky will only be able to purchase recreational cannabis legally in bordering Illinois, whenever this will be permitted. Starting in 2023, however, Kentuckians will be able to buy recreational cannabis legally in Michigan.
This growing medical use of cannabis is also motivating many companies such as India Globalization Capital Inc. (NYSE American: IGC) to go a step further and develop cannabinoid-derived formulations which, once FDA approved, could be available through the hospital system.
NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
